Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mineralys Therapeutics, Inc. - Common Stock (NQ: MLYS )

13.79 +1.02 (+7.95%)
Streaming Delayed Price Updated: 11:46 AM EST, Dec 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 179,492
Open 12.78
Bid (Size) 13.74 (8)
Ask (Size) 13.83 (2)
Prev. Close 12.77
Today's Range 12.52 - 14.19
52wk Range 6.378 - 16.91
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For November 11, 2024
Via Benzinga
Insights into Mineralys Therapeutics's Upcoming Earnings
Via Benzinga

Performance

YTD
+58.81%
+58.81%
1 Month
+2.49%
+2.49%
3 Month
+15.36%
+15.36%
6 Month
+5.39%
+5.39%
1 Year
+104.53%
+104.53%

More News

Read More
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Mineralys Therapeutics Earnings Preview
Via Benzinga
Where Mineralys Therapeutics Stands With Analysts
Via Benzinga
Where Mineralys Therapeutics Stands With Analysts
Via Benzinga
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
MLYS Investors Have Opportunity to Join Mineralys Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 21, 2024
Via Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy
From Praxis Bioresearch, Inc.
Via GlobeNewswire
$5M Bet On TreeHouse Foods? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Earnings Scheduled For March 15, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Via Benzinga
Around $11M Bet On Insight Enterprises? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.